Sleepy Don: Let's Take An Honest, Deeper Look at Trump’s Cognitive and Physical Decline

Is Donald Trump receiving treatment for early-stage Alzheimer’s disease?

The speculation centers on two datapoints: the now-famous bruise on the back of his right hand, and news that #Trump recently received an MRI.

A viral video by a medical professional suggested that the bruise pattern and the MRI schedule mirror the monthly infusion regimen for #Kisunla (#donanemab), an #Alzheimer’s drug that requires patients to undergo regular brain imaging to monitor for ARIA, a potentially dangerous swelling or bleeding.

https://michaeldsellers.substack.com/p/sleepy-don-lets-take-an-honest-deeper

FDA Approves Label Change for Alzheimer’s Drug

Brain edema risk expected to be less with new donanemab dosing schedule

The real question is whether it works?

https://cnmri.com/2025/07/14/fda-approves-label-change-for-alzheimers-drug/

#alzheimers #dementia #kisunla #donanemab #fda #brainedema

Did a new Alzheimer's drug keep this patient's brain healthier for longer?

New drugs Leqembi and Kisunla may have a modest benefit, don't cure #Alzheimer's, have a host of side effects (including brain bleeds), are troublesome to use (require IV infusion or injection) and multiple brain scans and cost 10's of thousands to administer.

"I think it helped," says her husband, Ken Bell. "But I'm not sure."

That sort of uncertainty is common when it comes to #Leqembi and #Kisunla…

Both drugs clear the brain of a substance called beta-#amyloid, which forms the sticky plaques associated with #Alzheimers.

https://www.stlpr.org/npr/2025-02-26/did-a-new-alzheimers-drug-keep-this-patients-brain-healthier-for-longer

Will this be the death knell for Alzheimer’s monoclonal antibody treatments 🤔

Preprint on #Alzheimers drug deaths ignites dispute among authors

“Infighting among a group of prominent Alzheimer’s disease researchers has led to the withdrawal of a preprint they co-authored, which suggested a new Alzheimer’s drug markedly increases the risk of death. One scientist involved in the work charges the senior author failed to seek the go-ahead from his co-authors before posting an edited version of the article to a preprint server.”

#Lecanemab #Donanemab #Kisunla #amyloid #dementia
https://www.science.org/content/article/preprint-alzheimer-s-drug-deaths-ignites-dispute-among-authors

Another very expensive drug for Alzheimer’s disease, with lots of side effects and unclear benefit

FDA OKs Another Drug for Early #Alzheimer's Disease

The FDA approved #donanemab (#Kisunla) for the treatment of adults with early symptomatic #Alzheimers disease with confirmed amyloid pathology, the agency announcedopens in a new tab or window Tuesday. This includes Alzheimer's patients with mild cognitive impairment and mild #dementia.

The once-monthly treatment is the only anti-amyloid agent with evidence to support stopping therapy when amyloid plaques

https://www.medpagetoday.com/neurology/alzheimersdisease/110934

Via #CNN

The US #FoodAndDrugAdministration on Tuesday approved #donanemab, a #MonoclonalAntibody designed to slow the progression of early symptomatic #Alzheimer’s disease

Donanemab, made by #Indianapolis-based #EliLilly, works by helping body remove #AmyloidPlaque buildup in the brain, a hallmark of Alzheimer’s disease

It will be sold under the name #Kisunla and would cost $695/vial b4 insurance, what would amount to $12,522 for a 6-month course

#FDA

https://www.cnn.com/2024/07/02/health/lilly-azheimers-donanemab-fda/index.html